NCT04669132 (OLNEPA) is a Phase 2 clinical trial of Olanzapine in Nausea Post Chemotherapy, sponsored by Instituto Brasileiro de Controle do Cancer.

Who is sponsoring NCT04669132?

NCT04669132 is sponsored by Instituto Brasileiro de Controle do Cancer.

What drugs are being tested in NCT04669132?

Interventions in NCT04669132: Olanzapine, Netupitant, Palonesetron.

What condition does NCT04669132 study?

NCT04669132 studies Nausea Post Chemotherapy.

Is NCT04669132 still recruiting?

NCT04669132 is currently completed. Last updated 23 February 2022.

Last reviewed 2022-02-23 · How we verify

NCT04669132: OLNEPA

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Efficacy of Olanzapine, Netupitant and Palonosetron in Controlling Nausea and Vomiting Associated With Highly Emetogenic Chemotherapy in Patients With Breast Cancer

Completed Phase 2 Last updated 23 February 2022

What this trial tests

Phase 2 trial testing Olanzapine in Nausea Post Chemotherapy in 50 participants. Completed in 17 January 2022.

Timeline

17 December 2020

Primary endpoint
17 December 2021

17 January 2022

Quick facts

Lead sponsor	Instituto Brasileiro de Controle do Cancer
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	prevention
Enrollment	50
Start date	17 December 2020
Primary completion	17 December 2021
Estimated completion	17 January 2022
Sites	1 location across Brazil

Drugs / interventions tested

Olanzapine (olanzapine) — full drug profile →
Netupitant (NETUPITANT) — full drug profile →
Palonesetron — full drug profile →

Conditions studied

Nausea Post Chemotherapy — all drugs for Nausea Post Chemotherapy →

Sponsor

Instituto Brasileiro de Controle do Cancer — full company profile →

Who can join

18 and older, female only, with Nausea Post Chemotherapy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a longitudinal, one arm, prospective phase II study, designed to evaluate the efficacy of Olanzapine Netupitant and Palonosetron in the controll of nausea and vomiting induced by highly emetogenic chemotherapy.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Omission of dexamethasone in prophylaxis for highly emetogenic chemotherapy in patients with breast cancer.
Rebouças CV, Alves RB, Yamada AMTD, Del Giglio A, et al · · 2025 · PMID 40367007 · DOI 10.31744/einstein_journal/2025ao1124
Efficacy of Olanzapine, Netupitant, and Palonosetron in Controlling Nausea and Vomiting Associated with Highly Emetogenic Chemotherapy in Patients with Breast Cancer (OLNEPA)
de Rebouças CV, Alves RdB, Yamada AMTD, Giglio AD, et al · · 2023 · DOI 10.21203/rs.3.rs-2777459/v1

Verify or expand the search:

Other trials of Olanzapine

Trials testing the same drug.

NCT07442890 — A Cohort Study on the Prevention of Nausea and Vomiting Induced by Concurrent Chemoradiotherapy for Lung Cancer Using Ro · NA · not yet recruiting
NCT07482891 — An Exploratory Study on Efficacy and Safety of Fosaprepitant and Palonosetron Hydrochloride for Injection in Preventing · Phase 4 · not yet recruiting
NCT07208305 — Olanzapine Plus Metoclopramide for the Prevention of Opioid-Induced Nausea and Vomiting · Phase 3 · recruiting
NCT06995508 — Olanzapine for Managing Anorexia in Head and Neck Cancer Patients Undergoing Chemoradiation, MACRO Trial · Phase 2 · recruiting
NCT06554613 — Olanzapine Impact on First-line Immunotherapy for Advanced EGFR-negative NSCLC · Phase 2 · not yet recruiting

Other Instituto Brasileiro de Controle do Cancer trials

Trials by the same sponsor.

NCT05665920 — Efficacy and Safety of Ultra_HYPofractionated RadiotHerapy in Women With BrEast CaNcer Receiving Regional Nodal Radiatio · NA · recruiting
NCT04669873 — Accelerated Partial Breast Irradiation Versus Standard or Hypofractionated Whole-Breast Irradiation, in Early Breast Can · NA · recruiting
NCT04834570 — Breast Cancer Survivors: Main Physical and Psychosocial Problems After Completion of Treatment · unknown
NCT05050890 — Prognostic Value of Circulating Tumor DNA Dosing in Patients in Neoadjuvant Breast Neoplasia · unknown
NCT04505111 — Prehabilitation Plus ERAS vs ERAS in Gynecological Surgery · NA · withdrawn

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04669132 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Instituto Brasileiro de Controle do Cancer
Last refreshed: 23 February 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04669132.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing